A new 4-nitrobenzyl carbonate prodrug of methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate for potential use with nitroreductase-based gene-directed enzyme prodrug therapy (GDEPT)

C Asche; U Kucklaender

doi:10.1002/chin.200628210

A new 4-nitrobenzyl carbonate prodrug of methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate for potential use with nitroreductase-based gene-directed enzyme prodrug therapy (GDEPT)

Pharmazie. 2006 Mar;61(3):244-5. doi: 10.1002/chin.200628210.

Authors

C Asche¹, U Kucklaender

Affiliation

¹ LEDSS, UMR CNRS 5616, Université Joseph Fourier, Grenoble, France. [email protected]

PMID: 16599269
DOI: 10.1002/chin.200628210

Abstract

A tumour-selective 4-nitrobenzyloxycarbonyl prodrug methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate was synthezised for gene-directed enzyme prodrug therapy (GDEPT). The compound is a substrate for E. coli nitroreductase.

MeSH terms

Carbazoles / chemistry*
Carbazoles / metabolism
Carboxylic Acids / chemistry*
Carboxylic Acids / metabolism
Enzyme Therapy*
Enzymes / administration & dosage
Escherichia coli / enzymology
Genetic Therapy*
Nitroreductases / metabolism*
Prodrugs*

Substances

Carbazoles
Carboxylic Acids
Enzymes
Prodrugs
methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo(b)carbazole-1-carboxylate
Nitroreductases